Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells

BMC Urology

Volumn 8, Issue 1, 2008, Pages

  Suttmann, Henrik ^a   Retz, Margitta ^b   Paulsen, Friedrich ^c   Harder, Jürgen ^d   Zwergel, Ulrike ^a   Kamradt, Jörn ^a   Wullich, Bernd ^a   Unteregger, Gerhard ^a   Stöckle, Michael ^a   Lehmann, Jan ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CECROPIN A; CECROPIN B; LACTATE DEHYDROGENASE; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; ANTINEOPLASTIC AGENT; CECROPIN B PROTEIN, INSECTA; INSECT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; COLORIMETRY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MOUSE; NONHUMAN; SCANNING ELECTRON MICROSCOPY; BLADDER TUMOR; CELL CULTURE; CELL MEMBRANE; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; BROMODEOXYURIDINE; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INSECT PROTEINS; MICROSCOPY, ELECTRON, SCANNING; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 41549110793     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-8-5     Document Type: Article

References (31)

1. Cancer statistics, 2005. A Jemal T Murray E Ward A Samuels RC Tiwari A Ghafoor EJ Feuer MJ Thun, CA Cancer J Clin 2005 55 10 30 15661684
2. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. F Millan-Rodriguez G Chechile-Toniolo J Salvador-Bayarri J Palou F Algaba J Vicente-Rodriguez, J Urol 2000 164 680 684 10.1016/S0022-5347(05)67280-1 10954628
3. Guidelines on bladder cancer. W Oosterlinck B Lobel G Jakse PU Malmström M Stöckle CN Sternberg, Eur Urol 2002 41 105 112 10.1016/S0302-2838(01)00026-4 12074395
4. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. HW Herr DM Schwalb ZF Zhang PC Sogani WR Fair WF Whitmore Jr HF Oettgen, J Clin Oncol 1995 13 1404 1408 7751885
5. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. RJ Sylvester M A.P. DL Lamm, J Urol 2002 168 1964 1970 10.1016/S0022-5347(05)64273-5 12394686
6. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. DL Lamm BA Blumenstein JD Crissman JE Montie JE Gottesman BA Lowe MF Sarosdy RD Bohl HB Grossman TM Beck JT Leimert ED Crawford, J Urol 2000 163 1124 1129 10.1016/S0022-5347(05)67707-5 10737480
7. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. RJ Sylvester AP van der Meijden JA Witjes K Kurth, J Urol 2005 174 86 91 10.1097/01.ju.0000162059.64886. 1c 15947584
8. The current status of intravesical therapy for superficial bladder cancer. JJ Patard A Rodriguez B Lobel, Curr Opin Urol 2003 13 357 362 10.1097/00042307-200309000-00002 12917511
9. The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. RJ Sylvester M AP W Oosterlinck W Hoeltl AV Bono, Eur Urol 2003 44 423 428 10.1016/S0302-2838(03)00371-3 14499675
10. Cell-free immunity in Cecropia. A model system for antibacterial proteins. HG Boman I Faye GH Gudmundsson JY Lee DA Lidholm, Eur J Biochem 1991 201 23 31 10.1111/j.1432-1033.1991.tb16252.x 1915368
11. Solid-phase synthesis of cecropin A and related peptides. D Andreu RB Merrifield H Steiner HG Boman, Proc Natl Acad Sci USA 1983 80 6475 6479 6579533 10.1073/pnas.80.21.6475
12. Molecular cloning, cDNA sequencing, and chemical synthesis of cecropin B from Hyalophora cecropia. P van Hofsten I Faye K Kockum JY Lee KG Xanthopoulos IA Boman HG Boman A Engstrom D Andreu RB Merrifield, Proc Natl Acad Sci USA 1985 82 2240 2243 3857578 10.1073/pnas.82.8.2240
13. Antibiotic peptides as mediators of innate immunity. M Zasloff, Curr Opin Immunol 1992 4 3 7 10.1016/0952-7915(92)90115-U 1596366
14. Antibacterial peptides: basic facts and emerging concepts. HG Boman, J Intern Med 2003 254 197 215 10.1046/j.1365-2796.2003.01228.x 12930229
15. N-terminal analogues of cecropin A: synthesis, antibacterial activity, and conformational properties. D Andreu RB Merrifield H Steiner HG Boman, Biochemistry 1985 24 1683 1688 10.1021/bi00328a017 3924096
16. Structure and functions of channel-forming peptides: magainins, cecropins, melittin and alamethicin. B Bechinger, J Membr Biol 1997 156 197 211 10.1007/s002329900201 9096062
17. Effects of the anti-bacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer cells. HM Chen W Wang D Smith SC Chan, Biochim Biophys Acta 1997 1336 171 179 9305787
18. Preliminary experimental anticancer activity of cecropins. AJ Moore DA Devine MC Bibby, Pept Res 1994 7 265 269 7849420
19. Structure-antitumor and hemolytic activity relationships of synthetic peptides derived from cecropin A-magainin 2 and cecropin A-melittin hybrid peptides. SY Shin MK Lee KL Kim KS Hahm, J Pept Res 1997 50 279 285 9352466
20. Enhancement of the cytolytic effect of anti-bacterial cecropin by the microvilli of cancer cells. SC Chan L Hui HM Chen, Anticancer Res 1998 18 4467 4474 9891511
21. Expression of antimicrobial peptides has an antitumour effect in human cells. D Winder WH Gunzburg V Erfle B Salmons, Biochem Biophys Res Commun 1998 242 608 612 10.1006/bbrc.1997.8014 9464264
22. Antitumor Activity of the Antimicrobial Peptide Magainin II against Bladder Cancer Cell Lines. J Lehmann M Retz SS Sidhu H Suttmann M Sell F Paulsen J Harder G Unteregger M Stöckle, Eur Urol 2006 50 141 147 10.1016/j.eururo.2005.12.043 16476519
23. A new serial transfer explant cell culture system for human prostatic cancer tissues preventing selection toward diploid cells. T Zwergel H Kakirman H Schorr B Wullich G Unteregger, Cancer Genet Cytogenet 1998 101 16 23 10.1016/S0165-4608(97)00062-9 9460495
24. Cancer immunoediting: from immunosurveillance to tumor escape. GP Dunn AT Bruce H Ikeda LJ Old RD Schreiber, Nat Immunol 2002 3 991 998 10.1038/ni1102-991 12407406
25. Host defense peptides as new weapons in cancer treatment. N Papo Y Shai, Cell Mol Life Sci 2005 62 784 790 10.1007/s00018-005-4560-2 15868403
26. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. N Papo D Seger A Makovitzki V Kalchenko Z Eshhar H Degani Y Shai, Cancer Res 2006 66 5371 5378 10.1158/0008-5472.CAN-05-4569 16707464
27. Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. N Papo N Braunstein Z Eshhar Y Shai, Cancer Res 2004 64 5579 5786 10.1158/0008-5472.CAN-04-1438
28. Physicochemical determinants for the interactions of magainins 1 and 2 with acidic lipid bilayers. K Matsuzaki M Harada S Funakoshi N Fujii K Miyajima, Biochim Biophys Acta 1991 1063 162 170 10.1016/0005-2736(91)90366-G 2015255
29. Identification of serum components that inhibit the tumoricidal activity of amphiphilic alpha helical peptides. KA Peck-Miller RP Darveau HP Fell, Cancer Chemother Pharmacol 1993 32 109 115 10.1007/BF00685612 8485805
30. Antitumor activity of magainin analogues against human lung cancer cell lines. Y Ohsaki AF Gazdar HC Chen BE Johnson, Cancer Res 1992 52 3534 3538 1319823
31. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. JL Au RA Badalament MG Wientjes DC Young JA Warner PL Venema DL Pollifrone JD Harbrecht JL Chin SP Lerner BJ Miles, J Natl Cancer Inst 2001 93 597 604 10.1093/jnci/93.8.597 11309436